The Effects of Rheumatoid Arthritis on Labor Force Participation, Work Performance, and Healthcare Costs in Two Workplace Samples
Authors:
- Ronald C. KesslerRKRonald C. Kessler
- J Ross MacleanJMJ Ross Maclean
- Maria PetukhovaMPMaria Petukhova
- Chaitanya A. SarawateCSChaitanya A. Sarawate
- Louise ShortLSLouise Short
- Tracy T. LiTLTracy T. Li
- Paul E. StangPSPaul E. Stang
- 1 January 2008
- journal article
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 50 (1) , 88-98
Abstract
To assess the workplace costs of rheumatoid arthritis (RA) from the employer perspective. Samples included 4485 manufacturing firm (MF) employees (109 with RA) and 915 commercially insured (CO) subscribers (333 with RA). Respondents completed the Health and Work Performance Questionnaire (HPQ) and the Health Assessment Questionnaire (HAQ). The effects of RA were estimated using regression analysis. RA was associated with increased probability of no longer working (CO), increased effort to maintain work performance (CO), increased sickness absence (MF), and increased non-RA pharmacy costs (CO). RA was not associated with hours worked or hourly wage. Indirect costs of RA did not exceed direct medical costs. Indirect costs of RA to employers are significant and warrant further research to increase our understanding of the contribution of different RA treatment interventions to optimizing workforce productivity.Keywords
This publication has 40 references indexed in Scilit:
- Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic ReviewSeminars in Arthritis and Rheumatism, 2006
- Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid ArthritisJournal of Managed Care Pharmacy, 2006
- Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again)Rheumatology, 2006
- Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in SwedenAnnals of the Rheumatic Diseases, 2005
- Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid ArthritisDrugs, 2005
- An Overview of Economic Evaluations for Drugs Used in Rheumatoid ArthritisDrugs, 2005
- Modeling the 5‐year cost effectiveness of treatment strategies including tumor necrosis factor‐blocking agents and leflunomide for treating rheumatoid arthritis in the NetherlandsArthritis Care & Research, 2004
- EtanerceptPharmacoEconomics, 2004
- Rheumatoid arthritisThe Lancet, 2001
- The costs of rheumatoid arthritis: an international long-term viewSeminars in Arthritis and Rheumatism, 2000